A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.

ABSTRACT:

Background

Etanercept plus methotrexate combination therapy has not been adequately investigated in psoriasis.

Objectives

To evaluate etanercept plus methotrexate vs. etanercept monotherapy in patients with moderate to severe plaque psoriasis who had not failed prior methotrexate or tumour necrosis factor-inhibitor therapy.

Methods

Patients received etanercept 50 mg twice weekly for 12 weeks followed by 50 mg once weekly for 12 weeks and were randomized 1 : 1 to receive methotrexate (7·5-15 mg weekly) or placebo. The primary endpoint was the proportion of patients achieving ≥75% improvement in Psoriasis Area and Severity Index (PASI 75) at week 24.

Results

In total, 239 patients were enrolled in each arm. PASI 75 was significantly higher at week 24 for the comb

SUBMITTER: Gottlieb AB 

PROVIDER: S-EPMC3504074 | biostudies-literature | 2012 Sep

REPOSITORIES: biostudies-literature